---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000085"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:36:19.757900+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics receives Nasdaq delisting notice for MVLS non-compliance

## Summary
- Nasdaq notified vTv on Dec 13, 2023 that MVLS was below $35M for 30 consecutive business days.
- Company has 180 calendar days, until June 10, 2024, to regain compliance.
- To regain compliance, MVLS must close at $35M or more for 10 consecutive business days.
- Failure to cure may result in delisting of Class A common stock from Nasdaq Capital Market.
- Company is evaluating options but offers no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001641489-23-000085
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000085/0001641489-23-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000085/vtvt-20231213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000085
- JSON: https://secwatch.observer/filing/0001641489-23-000085.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000085.txt

## Key facts
- Listing & Compliance Notices
  vTv Therapeutics Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: market value
  - Rules: 5550(b)(2), 5810(c)(3)(C)
  source text: December 13, 2023, vTv Therapeutics Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement of Nasdaq Listing Rule 5550(b)(2) because the Company's listed securities have been below the required market value of listed securities (MVLS) of $35 million for the last 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until June 10, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(2). Compliance can be achieved without f
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000085/0001641489-23-000085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.